Login to Your Account



Acorda Gains Zanaflex Rights From Elan; New Capsule Soon

By Randall Osborne


Friday, July 30, 2004
With its own product for multiple sclerosis and spinal cord injuries already in the works, Acorda Therapeutics Inc. acquired from Elan Corp. plc all U.S. rights to oral Zanaflex (tizanidine), a marketed treatment for spasticity in patients with those conditions. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription